Background/Objectives: TDP-43 mutation-driven Amyotrophic Lateral Sclerosis (ALS) motor neuron disease is one of the most prominent forms (approximately 97%) in cases of sporadic ALS. Dysfunctional autophagy and lysosomal function are the prime mechanisms behind ALS. Mitoxantrone (Mito), a synthetic doxorubicin analog, is an inhibitor of DNA and RNA synthesis/repair via intercalating with nitrogenous bases and inhibiting topoisomerase II. The therapeutic potential of miRNAs associated with disease conditions has also been reported. This study explores the therapeutic potential of Mito along with miRNAs against mutated TDP-43 protein-induced proteinopathy in human-induced pluripotent stem cell (hiPSC)-derived human neural progenitor cells (hNPCs). Methods: HiPSCs mutated for TDP-43 were differentiated into hNPCs and used to explore the therapeutic potential of Mito at a concentration of 1 μM for 24 h (the identified non-cytotoxic dose). The therapeutic effects of Mito on miRNA expression and various cellular parameters such as mitochondrial dynamics, autophagy, and stress granules were assessed using the high-throughput Open Array technique, immunocytochemistry, flow cytometry, immunoblotting, and mitochondrial bioenergetic assay. Results: Mutated TDP-43 protein accumulation causes stress granule formation (G3BP1), mitochondrial bioenergetic dysfunction, SOD1 accumulation, hyperactivated autophagy, and ER stress in hNPCs. The mutated hNPCs also show dysregulation in six miRNAs (miR-543, miR-34a, miR-200c, miR-22, miR-29b, and miR-29c) in mutated hNPCs. A significant restoration of TDP-43 mutation-induced alterations could be witnessed upon the exposure of mutated hNPCs to Mito. Conclusions: Our study indicates that miR-543, miR-29b, miR-22, miR-200c, and miR-34a have antisense therapeutic potential alone and in combination with Mitoxantrone.
Periodontitis is regarded as the 6th microvascular complication of type 2 diabetes mellitus (T2DM). In individuals with both periodontitis and T2DM, the condition may adversely influence the regenerative potential of the platelet-rich fibrin (PRF) and hyperacute serum (HAS) derived from these patients. The present cross-sectional study was conducted to evaluate the weight and cytokine levels of the PRF and HAS obtained from periodontitis patients with or without T2DM in a laboratory setting. Platelet-rich fibrin and HAS were obtained from 17 periodontitis patients with T2DM (group 1: T2DM+/P+), 17 periodontitis patients without T2DM (group 2: T2DM-/P+), and 16 periodontally healthy participants (group 3: T2DM-/P-). Demographic, periodontal and hematological parameters were recorded for all participants. Serum, PRF and HAS samples were quantified and analyzed for inflammatory markers - interleukin-6 (IL-6), resistin (RETN), tumor necrosis factor-alpha (TNF-α), IL-1β, and interleukin-1 receptor antagonist (IL-1ra) - as well as growth factors, including insulin-like growth factor-1 (IGF-1), transforming growth factor-beta 1 (TGF-β1), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor-21 (FGF-21). The quantities of PRF and HAS obtained were significantly higher in healthy individuals as compared to diabetic patients. The concentrations of inflammatory markers and growth factors in serum, PRF and HAS from periodontitis patients were not significantly different between those with and without T2DM. Periodontitis in conjunction with T2DM may influence the weight of PRF and HAS; however, no significant association was observed with respect to the levels of inflammatory markers and growth factors.